|
|
|
|
Neck Cancer
Wellness calendar 14 Mar 2006
Indianapolis Star, Call (317) 877-1325. Head and Neck Cancer Support Group: 7 pm the third Tuesday of every month at Lawrence Public Library, 7898 Hague Road. ...
German Pharma Powerhouse Potential 14 Mar 2006
BusinessWeek The deal would create a much stronger player in oncology. Merck's colorectal-cancer drug Erbitux was recently approved to treat head and neck cancer. ...
FDA Approves First Head & Neck Cancer Treatment in 45 Years Mar 10, 2006
Rocklin and Roseville Today, This is the first drug approved for head and neck cancer that has shown a survival benefit in this population. Erbitux was also ...
Physician Focus: Health care from the neck up: cancer check Mar 9, 2006
Tewksbury Advocate, ...sinusitis, snoring and sleep apnea, hearing loss, allergies and hay fever, swallowing disorders, nosebleeds, hoarseness, dizziness, and head and neck cancer. ...
FDA OKs Erbitux for Head & Neck Cancer Mar 2, 2006
FOX News It’s the first drug approved for head and neck cancer that has shown a survival benefit in this population, according the FDA. ...
FDA approves Erbitux for head, neck cancer Mar 1, 2006
Reuters WASHINGTON/NEW YORK (Reuters) - US regulators on Wednesday approved ImClone Systems Inc.'s colon cancer drug Erbitux to treat head and neck cancer in cases ...
Update 2: Erbitux Approved for Head, Neck Cancer Mar 1, 2006
Forbes Federal regulators on Wednesday approved Erbitux as the first new drug to treat head and neck cancer since the 1950s. The Food and ...
Head, neck cancer drug in Martha Stewart trial gets federal OK Mar 1, 2006
Newsday, ...on Wednesday approved Erbitux, the drug at the center of the Martha Stewart stock scandal, as the first new drug to treat head and neck cancer since the 1950s. ...
FDA approves new drug for head & neck cancer Mar 3, 2006
Cancerfacts.com, ROCKVILLE, Md. – Mar. 2, 2006 – The FDA today approved the first new drug in 45 years for treatment of a type of head and neck cancer. ...
FDA Approves Erbitux To Treat Head And Neck Cancer Mar 2, 2006
All Headline News The FDA says in its announcement Thursday that this is the first drug approved for head and neck cancer that has shown a survival benefit in this population. ...
FDA Approves Erbitux For Treatment Of Head And Neck Cancer Mar 2, 2006
Playfuls.com, ...by Playfuls Team. Last year alone, nearly 40,000 Americans were diagnosed with head and neck cancer, and 11,000 died from the disease. ...
Erbitux gets federal OK as first head-and-neck cancer drug since ... Mar 1, 2006
SouthCoastToday.com, By THE ASSOCIATED PRESS. WASHINGTON — Federal regulators yesterday approved Erbitux as the first new drug to treat head and neck cancer since the 1950s. ...
Erbitux approved for head and neck cancer in US Mar 3, 2006
Pharmaceutical Business Review ...a molecular structure linked to tumor growth - Erbitux is the first and only monoclonal antibody to be approved for the treatment of head and neck cancer. ...
FDA Approves Erbitux for Squamous Cell Head-and-Neck Cancer Mar 2, 2006
MedPage Today, ...marks the first time in 45 years, since it allowed methotrexate on the market, that it has approved a drug for treatment of this type of head-and-neck cancer. ...
New Drug For Head & Neck Cancer Mar 2, 2006
KOLD-TV, The drug already is on the market. It's used to treat colorectal cancer. This is the first new drug approved for head and neck cancer since the 1950's. ...
FDA approves new drug to treat head-and-neck cancer Mar 1, 2006
WBNS, The Food and Drug Administration says Erbitux (UR'-bih-tuks) may now be used to treat squamous cell cancer of the head and neck that cannot be removed by ...
New Erbitux approval to head off cancer Mar 6, 2006
In-PharmaTechnologist.com, 06/03/2006 - Last week’s approval of Erbitux in the US breaks a 30-year drought in treatments for head and neck cancer, a disease that kills 11,000 people in ...
Subcutaneous Amifostine Feasible During Radiotherapy for Head and ... Mar 1, 2006
Cancerpage.com, ...subcutaneous amifostine to reduce the toxic effects of radiation therapy and chemotherapy is feasible in patients with head and neck cancer, Swiss physicians ...
Radiation Therapy and Combination Chemotherapy for Head and Neck ... Mar 8, 2006
Cancer Consultants (press release), Among selected patients with head and neck cancer that has not yet spread to distant sites in the body, combination chemotherapy and radiation therapy appears ...
Erbitux recommended in Europe for head and neck cancer Feb 24, 2006
Pharmaceutical Business Review Medicinal Products for Human Use has recommended that European regulators approve Merck KGaA's application for the cancer drug Erbitux in head and neck cancer. ...
FDA Approves Erbitux® For Treatment of Head and Neck Cancer Mar 2, 2006
Cancer Consultants (press release), The United States Food and Drug Administration (FDA) has approved the monoclonal antibody Erbitux® (cetuximab) for the treatment of head and neck cancer. ...
Erbitux gets US green light for head and neck cancer Mar 2, 2006
Pharma Times (subscription), ...and Drug Administration (FDA) for use in combination with radiation therapy in the treatment of locally or regionally advanced head and neck cancer, and as a ...
Drug approved to treat head, neck cancer Mar 1, 2006
Austin American-Statesman (subscription), WASHINGTON — Federal regulators Wednesday approved Erbitux as the first new drug to treat head and neck cancer since the 1950s. ...
New Ideas Fuel Next Generation Gene Therapy Research Mar 7, 2006
eMaxHealth.com, To date, at MD Anderson, gene therapy experiments are ongoing, or starting within several months, in metastatic lung cancer, head and neck cancer, and brain ...
CEL-SCI Corporation Releases Letter to Shareholders Mar 8, 2006
International News Service, The long-term follow-up study of the head & neck cancer patients who received Multikine over 3 years ago showed a substantial improvement in both the survival ...
Erbitux OK’d for Other Cancer Mar 2, 2006
Red Herring, ImClone Systems and Bristol-Myers Squibb’s cancer drug gets approval for another type of head and neck cancer. ImClone Systems ...
Erbitux Approved for Head, Neck Cancer Mar 1, 2006
Newsday, By Associated Press. WASHINGTON -- Federal regulators on Wednesday approved Erbitux as the first new drug to treat head and neck cancer since the 1950s. ...
US FDA OKs Erbitux to treat head and neck cancer Mar 1, 2006
Reuters IMCL.O: Quote, Profile, Research) and Bristol-Myers Squibb Co's (BMY.N: Quote, Profile, Research) drug Erbitux to treat head and neck cancer that cannot be ...
Erbitux Approved for Treatment of Head and Neck Cancer Mar 3, 2006
Daily News Central, ...the new use for the drug based on a study that showed Erbitux, in combination with radiation therapy, prolonged the lives of head and neck cancer patients by ...
FDA OKs Drug for Head & Neck Cancer Mar 2, 2006
WebMD It's the first drug approved for head and neck cancer that has shown a survival benefit in this population, according the FDA. The ...
FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck ... Mar 1, 2006
Genetic Engineering News, ...a molecular structure linked to tumor growth - ERBITUX is the first and only monoclonal antibody to be approved for the treatment of head and neck cancer. ...
Unique breast cancer therapy treats 100th patient at clinic Mar 10, 2006
Saanich News, The therapy was initially used on head and neck cancer patients and is now available for those patients across the province. The ...
FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck ... Mar 1, 2006
Finanzen.net, These indications arebased on a Phase III study - one of the largest studies ever conductedin head and neck cancer patients - that demonstrated a survival ...
Remember Sam Waksal Mar 11, 2006
Capitalism Magazine, ...toll from the FDA even higher. Last week the FDA approved Erbitrux for head and neck cancer. The drug is "the first significant ...
Chemotherapy plus Radiation Therapy Superior to Aggressive ... Mar 7, 2006
Cancer Consultants (press release), ...be surgically removed. Approximately 40,000 people in the US are diagnosed with head and neck cancer every year. Cancers of the ...
Erbitux Approved to Treat Head and Neck Cancers Mar 9, 2006
HealthCentral.com The drug Erbitux has been approved to treat head and neck cancer, according to the US Food and Drug Administration. The drug, which ...
FDA gives greenlight for new treatment of head and neck cancer Mar 4, 2006
News-Medical.net, The US Food and Drug Administration has approved colon cancer drug Erbitux to treat head and neck cancer after results of a large clinical trial showed the ...
ImClone’s Erbitux Receives FDA Label In Head And Neck Cancer Mar 2, 2006
BioWorld Online (subscription), ...from partner Bristol-Myers Squibb Co., thanks to the FDA’s approval of the colorectal cancer drug Erbitux for the added indication of head and neck cancer. ...
(PRN) Recent FDA Action Validates ADVEXIN(R) Registration Strategy ... Mar 3, 2006
Houston Chronicle, ...said today it is encouraged by the recent US Food and Drug Administration (FDA) action approving a new therapy for patients who suffer from head and neck cancer ...
Biomarkers in Blood Detect Oral Cancer Mar 8, 2006
Cancer Consultants (press release), Oral cancer, or cancer of the mouth, is considered a type of head and neck cancer. Approximately 40,000 people in the US are diagnosed ...
Rehabilitation integral part of cancer surgery Mar 4, 2006
Newindpress (subscription), Club’ to mark ‘George W Crile’s Centenary’ at the seminar hall in Justice KS Hegde Charitable Hospital he said head and neck cancer cases were being ...
UPDATE 2-US FDA approves Erbitux for head and neck cancer Mar 1, 2006
Reuters US regulators on Wednesday approved ImClone Systems Inc.'s (IMCL.O: Quote, Profile, Research) colon cancer drug Erbitux to treat head and neck cancer in cases ...
Erbitux® Plus Chemotherapy and Radiation Therapy Promising in ... Mar 2, 2006
Cancer Consultants (press release), ...the combination of Erbitux® (cetuximab) plus chemotherapy and radiation therapy provides promising outcomes in the treatment of advanced head and neck cancer. ...
Erbitux Approved for Head and Neck Cancers Mar 2, 2006
Cancerpage.com, By Rachael Myers Lowe, cancerpage.com. ( March 1, 2006 ) – The FDA has approved the drug Erbitux (cetuximab) for use in head and neck cancer. ...
NHS cancer waiting times in Lothians are best in Scotland Mar 8, 2006
Scotsman, Lothian hospitals continue to lag behind the national average for seeing patients with melanoma, lymphoma and head and neck cancer within two months. ...
Erbitux Approved to Treat Head and Neck Cancers Mar 3, 2006
Forbes The FDA also approved Erbitux for treatment of patients with head and neck cancer whose cancer has spread despite treatment with chemotherapy. ...
MultiVu Video Feed: FDA Approves ERBITUX(R) (Cetuximab) for ... Mar 1, 2006
Finanzen.net, NEW YORK, March 1 /PRNewswire-FirstCall/ -- Last year alone, nearly 40,000 Americans were diagnosed with head and neck cancer, and 11,000 died from the disease ...
FDA approves new cancer drug Erbitux Mar 2, 2006
Monsters and Critics.com, WASHINGTON, DC, United States (UPI) -- The US Food and Drug Administration announced approval of the first new head and neck cancer treatment in 45 years. ...
Merck KGaA Receives EMEA Positive Opinion for Erbitux in Head and ... Feb 23, 2006
DG News ...committee of the EMEA (European Medicines Agency), for its application to extend the use of Erbitux® (cetuximab) to the treatment of head and neck cancer. ...
Cancer Concerns Mar 12, 2006
Ohio News Network, Two years ago Clyde school officials were devistated to learn that three local children had been diagnosed with head or neck cancer. ...
CORRECTED - UPDATE 2-US FDA approves Erbitux for head and neck ... Mar 1, 2006
Reuters In WASHINGTON/NEW YORK story headlined "UPDATE 2-US FDA approves Erbitux for head and neck cancer," please read in 11th paragraph ... ...
CORRECTED - UPDATE 2-US FDA approves Erbitux for head and neck ... Mar 2, 2006
Reuters In the March 1 WASHINGTON/NEW YORK story headlined "CORRECTED - UPDATE 2-US FDA approves Erbitux for head and neck cancer," please read at the beginning of the ...
BioVex Inc Begins Dosing Patients in Phase II Clinical Trials of ... Feb 14, 2006
CNW Telbec (Communiqués de presse), ...cancer announced today that the first patients in its phase II clinical trials of OncoVEXGMCSF in malignant melanoma and in head and neck cancer had received ...
��：生命�纬 Mar 1, 2006
BioX, Reuters) - US regulators on Wednesday approved ImClone Systems Inc.'s (Nasdaq:IMCL - news) colon cancer drug Erbitux to treat head and neck cancer in cases ...
CEL-SCI Updates On Its Cancer Drug Multikine - Quick Facts Mar 8, 2006
Trading Markets, ...long-term follow-up study of the head & neck cancer patients who received Multikine over 3 years ago showed a substantial improvement in both the survival rate ...
Erbitux Now Approved for Head and Neck Cancers Mar 3, 2006
ACS News Center, ..."We consider this approval an important advance in the treatment of head and neck cancer because it has been shown to help some patients live longer," said ...
FDA approves new cancer drug Erbitux Mar 2, 2006
Webindia123, The US Food and Drug Administration announced approval of the first new head and neck cancer treatment in 45 years. The FDA approved ...
Multikine Treatment Increases Survival in Cancer Patients Feb 21, 2006
PR Newswire (press release), 21 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announces positive results from a long-term follow-up study of head & neck cancer patients treated ...
ImClone Systems Issues Statement Regarding Positive Opinion from ... Feb 23, 2006
Genetic Engineering News, ..."We are pleased that our partners, Merck KGaA, may soon be able to offer ERBITUX to head and neck cancer patients in the European Union. ...
ImClone shares fall after expected drug approval Mar 2, 2006
Reuters ...a day after the biotechnology company received a widely expected additional approval to expand its colon cancer drug Erbitux to treat head and neck cancer. ...
Treatment with Chemotherapy and Radiation Therapy at the Same Time ... Feb 17, 2006
Cancer Consultants (press release), ...chemotherapy and radiation therapy at the same time improves outcomes compared to sequential administration in patients with advanced head and neck cancer. ...
Distribute a news release with PR Mar 5, 2006
Opinion Journal, Last Wednesday the FDA approved the drug for a new indication--head and neck cancer--based on data showing a whopping 20-month survival advantage over ...
Protein associated with growth of tumors may prevent the spread of ... Feb 13, 2006
News-Medical.net, ..."While the activation of STAT1 has been associated with increased survival in breast cancer patients, its role in head and neck cancer has not been clearly ...
Controversies: Is There a Role for Positron-Emission Tomographic ... Feb 16, 2006
Am J Neuroradiology (subscription) Bruschini P, Giorgetti A, Bruschini L, et al. Positron emission tomography (PET) in the staging of head neck cancer: comparison between PET and CT. ...
Multikine treatment increases survival in cancer patients Feb 21, 2006
News-Medical.net, CEL-SCI Corporation has announced positive results from a long-term follow-up study of head & neck cancer patients treated with its drug Multikine in a Phase ...
UPDATE 1-US FDA OKs Erbitux to treat head and neck cancer Mar 1, 2006
Reuters WASHINGTON, March 1 (Reuters) - The US Food and Drug Administration on Wednesday approved Erbitux to treat head and neck cancer in cases when surgery is not an ...
Im Clone Scandal Free And Developing New Treatments Mar 2, 2006
All Headline News ...fame. Researchers from the company have discovered a treatment for head and neck cancer with one of its previously approved drugs. ...
Old drugs find novel anti-cancer applications Feb 14, 2006
Xagena.it, Head and neck cancer is the sixth most common cancer world wide and in the United States there are approximately 40,000 new cases diagnosed annually and 10,000 ...
FDA OKs expanded Erbitux treatments Mar 1, 2006
CNN/Money Drug is first new therapy for head and neck cancer since the 1950s; drug could soon see $300-$400M in sales. WASHINGTON (Reuters ...
Anesthetic Gel Relieves Discomfort in Patients with Head and Neck ... Feb 17, 2006
Cancer Consultants (press release), Physics, use of an oral anesthetic gel relieves the pain experienced by patients with oral mucositis following radiation therapy for head and neck cancer. ...
ImClone Systems Issues Statement Regarding Positive Opinion from ... Feb 23, 2006
Finanzen.net, ..."We are pleased that our partners, Merck KGaA, may soon be able tooffer ERBITUX to head and neck cancer patients in the European Union.This is the first new ...
ImClone Outlook Boosted By New Erbitux-Use Approval Mar 2, 2006
Forbes Systems to $45 from $42 on higher long-term growth prospects related to the US Food and Drug Administration's approval of Erbitux use for head and neck cancer. ...
Addition of Erbitux® to Radiation Therapy Improves Survival in ... Feb 22, 2006
Cancer Consultants (press release), ...shown that the addition of Erbitux® (cetuximab) to radiation therapy improves survival over radiation therapy alone in the treatment of head and neck cancer. ...
ImClone advances Erbitux in three types of cancer Feb 20, 2006
Pharmaceutical Business Review The head and neck cancer study has enrolled 442 patients with recurrent and/or metastatic head and neck cancer who were randomized to receive cisplatin ...
Get A-Head names city solicitor as new head Mar 6, 2006
ic Birmingham.co.uk, ...of Birmingham Forward, joins University Hospital Birmingham's Get A-Head charity, which raises money for education and research into head and neck cancer. ...
Tetracaine mouthwash helps with pain linked to head and neck ... Feb 12, 2006
News-Medical.net, Doctors in Italy are studying whether a new type of mouthwash will help alleviate pain for patients suffering from head and neck cancer who were treated with ...
BioVex begins dosing in melanoma trial Feb 17, 2006
Pharmaceutical Business Review The first patients in BioVex' phase II trials of OncoVex GMCSF in malignant melanoma and in head and neck cancer have received their initial doses of the ...
Rinse away oral pain? Feb 21, 2006
myDNA.com, A newly developed mouthwash shows promise in easing oral pain experienced by patients undergoing radiation therapy for head and neck cancer. ...
Mouth gel curbs oral pain after cancer treatment Feb 14, 2006
Reuters Mouth inflammation and sores, or mucositis, are a common and serious side effect of radiation therapy for head and neck cancer patients. ...
(PRN) - Apartment Investment and Management Company to Participate ... Mar 3, 2006
Bolsamania.com, ...[+]. (PRN) - Recent FDA Action Validates ADVEXIN(R) Registration Strategy; Introgen Encouraged By Approval of Erbitux(R) for Head and Neck Cancer ... [+. ...
SURGEON GIVES STARK WARNING TO SMOKERS ON ORAL CANCER DANGER Mar 3, 2006
South Wales Evening Post, Last year the hospital dealt with 162 new cases of head and neck cancer and doctors are warning the figures are likely to increase. ...
ImClone Systems Announces Complete Enrollment of Several Studies ... Feb 16, 2006
Genetic Engineering News, The EXTREME study has enrolled 442 patients with recurrent and/or metastatic head and neck cancer who were randomized to receive cisplatin/carboplatin plus 5 ...
Gila Monster An Unlikely Help For Diabetics Mar 6, 2006
KDKA, ...weight. Dr. Paul Nemiroff is a nationally-recognized surgeon who specializes in head and neck cancer and reconstructive surgery. Watch ...
Many Factors Influence Drop in Cancer Deaths Mar 3, 2006
Wheeling Intelligencer, Chemotherapy improvements, particularly with regard to lung cancer, colorectal cancer, breast cancer, lymphomas, and head and neck cancer has improved over all ...
Merck KGaA receives positive opinion on Erbitux from EMEA - UPDATE Feb 23, 2006
Forbes FRANKFURT (AFX) - Merck KGaA said it received a positive opinion on its drug Erbitux to treat head and neck cancer from the European Medicines Agency (EMEA). ...
ImClone Systems Announces Complete Enrollment of Several Studies ... Feb 16, 2006
Finanzen.net, The EXTREME study has enrolled 442 patients with recurrent and/ormetastatic head and neck cancer who were randomized to receivecisplatin/carboplatin plus 5-FU ...
Biotec Pharmacon Announces Good Progress in ongoing Clinical ... Feb 28, 2006
PharmaLive.com (press release), ...parallel group study, comparing the protective effect of soluble beta-1,3/1,6-glucan or placebo in oral mucositis in head and neck cancer patients receiving ...
SNM’s Online Program Allows Physician Diplomates to Satisfy ... Mar 2, 2006
PressZoom (press release), Program modules to come include Introduction to Nuclear Brain Imaging; PET/CT Imaging: Evaluation of Patients With Head and Neck Cancer and Brain Tumors; PET ...
CEL-SCI Receives US Patent for Use of LEAPS(TM) Technology for ... Feb 28, 2006
Yahoo! News (press release) The Company's lead product Multikine® is cleared to enter Phase III clinical trials with advanced primary head and neck cancer patients. ...
RxKinetix Completes Its End of Phase 2 Meeting With the FDA for RK ... Mar 1, 2006
Yahoo! News (press release) Phase 3 development. RxKinetix recently completed a Phase 2 trial of RK-0202 in patients with head and neck cancer. The Phase 2 ...
Merck KGaA 2005 Profit After Tax Remains at High Level Feb 16, 2006
PharmaLive.com (press release), ...cancer. On December 21, 2005, Swissmedic granted Merck marketing authorization for the additional indication of head and neck cancer. ...
ImClone: Erbitux gets EU panel nod Feb 23, 2006
BusinessWeek Merck said in Europe about 100,800 people are diagnosed with head and neck cancer and almost 40,000 die from the disease every year. ...
ImClone: Erbitux Gets EU Panel Nod Feb 23, 2006
Houston Chronicle, Merck said in Europe about 100,800 people are diagnosed with head and neck cancer and almost 40,000 die from the disease every year.
ImClone, Merck KGaA Get Erbitux Recommendation From European Panel ... Feb 23, 2006
Canadian Business, NEW YORK (AP) - Biotech company ImClone Systems Inc. and German drug maker Merck KGaA said Thursday a European panel as recommended ...
AFX European summary - late Feb 23, 2006
Forbes FRANKFURT (AFX) - Merck KGaA said it received a positive opinion on its drug Erbitux to treat head and neck cancer from the European Medicines Agency (EMEA). ...
Merck FY EBIT, net misses consensus; Erbitux, LCD sales growth in ... Feb 16, 2006
Forbes In December the drug was approved for head and neck cancer in Switzerland, and an opinion on this is also expected from the European Medicines Agency (EMEA) in ...
(PRN) Access Pharmaceuticals Announces the Commencement of a New ... Feb 23, 2006
Houston Chronicle, The aim of the study, being conducted at the Moores Cancer Center at the University of California, San Diego in patients with head and neck cancer under a ...
18 F-FET PET Compared with 18 F-FDG PET and CT in Patients with ... Feb 14, 2006
Journal of Nuclear Medicine Conclusion: 18 F-FET may not replace 18 F-FDG in the PET diagnostics of head and neck cancer but may be a helpful additional tool in selected patients, because ...
(PRN) - Following Is a Test Release ... [+] Mar 1, 2006
Bolsamania.com, Dividend ... [+. PRN) - MultiVu Video Feed: FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck Cancer ... [+. PRN ...
QOL After Treatment of Head and Neck Cancer Predicts Long-Term ... 25 Jan 2006
Cancerpage.com, NEW YORK JAN 24, 2006 (Reuters Health) - A high quality of life (QOL) documented 1 year after treatment of primary epithelial head and neck cancer is strongly ...
Publication Alert from Introgen Therapeutics, Inc. 25 Jan 2006
PharmaLive.com (press release), ...received FDA Fast Track designation for ADVEXIN therapy and ADVEXIN has been designated as an Orphan Drug for the treatment of head and neck cancer under the ...
Quality of Life Predicts Head and Neck Cancer Survival Jan 18, 2006
Forbes 18 (HealthDay News) -- Poorer quality of life a year after treatment appears to predict diminished long-term survival for head and neck cancer patients, new ...
Quality of Life After Treatment with Head and Neck Cancer Jan 17, 2006
Kansas City infoZine, Chicago, Ill. - infoZine - Quality of life measured one year after treatment for head and neck cancer appears to be associated with longer-term survival ...
Quality of life after treatment for head and neck cancer ... Jan 16, 2006
News-Medical.net, Quality of life measured one year after treatment for head and neck cancer appears to be associated with longer-term survival, according to a study in the ...
US Stock-Index Futures Advance on Oil Drop, Lexmark Earnings Jan 24, 2006
Bloomberg The company also said it expects to increase its market share by winning approval of Erbitux next month for use in head and neck cancer. ...
Oral Mucositis Affects Care of Patients with Head and Neck Cancer Jan 11, 2006
Cancer Consultants (press release), In a study published in the journal Cancer, oral mucositis developed in over 80% of patients undergoing radiation therapy for head and neck cancer. ...
Quality of Life Associated with Long-Term Survival in Patients ... Jan 17, 2006
DG News CHICAGO, IL -- January 17, 2006 -- Quality of life measured one year after treatment for head and neck cancer appears to be associated with longer-term survival ...
CEL-SCI Corporation Releases Letter to Shareholders Jan 19, 2006
Biotech Intelligence (press release), ...is highly regarded world-wide and their approval is a major step in our goal of starting a world-wide Phase III trial for head & neck cancer with our partner ...
Merck KGaA Won't Change Pharmaceuticals Strategy, Schnee Says Jan 22, 2006
Bloomberg The drug received Swiss regulatory approval to treat head and neck cancer in December, the first time it had been certified for that use anywhere in the world. ...
Cel-Sci Catches Bad Case of the Biotech Blues Jan 22, 2006
Washington Post, After all, he noted, the firm's lead drug, a treatment for head and neck cancer, had received a patent allowing for 19 years of exclusivity. ...
Bahamas Makes Forward Step In Cancer Treatment Jan 13, 2006
The Bahama Journal, Porter said. Some of the common cases of cancer treated at the centre include breast, prostate and head and neck cancer. On average ...
Inovio Adds Significant Patents Relating to Electroporation ... Jan 11, 2006
Business Wire (press release), Inovio is moving its lead product, the MedPulser(R), through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark ...
Medical Assistant Knows Pain Of Confused Stares Jan 12, 2006
KETV.com, Schoo is on the front line, treating head and neck cancer patients as a medical assistant at the Nebraska Medical Center. "I like to give every patient a hug. ...
New funding for further cancer study Jan 19, 2006
Port Macquarie News, The technology en hancements will supply new equipment in cancer treatment for breast, prostate, gynaecological, bowel, head and neck cancer. ...
Introgen Updates Regulatory Guidance for ADVEXIN Therapy of Head ... Dec 23, 2005
Biotech Intelligence (press release), ADVEXIN therapy based upon the drug's known molecular mechanisms of action and further analyses of ADVEXIN's phase 2 clinical trial data in head and neck cancer ...
UK Cancer Patients Lack Access to Radiotherapy, Study Finds Jan 12, 2006
Bloomberg For head and neck cancer, patients who wait more than six weeks after being operated are three times as likely to have the disease reappear, he said. ...
Cancer patients put at risk by shortage of radiotherapy staff Jan 12, 2006
EurekAlert (press release), And for head and neck cancer, patients waiting more than six weeks for post-operative radiotherapy are three times as likely to have the cancer recur. ...
Hospital wait times longer for Mississauga Jan 12, 2006
Mississauga News, Depending on whether you go to Credit Valley Hospital or Trillium, you also face higher than normal wait times for prostrate, head and neck cancer surgery, as ...
Clinical Data, Inc. Announces Collaborative Research Agreement ... Jan 12, 2006
Genetic Engineering News, Graduate School of Public Health and also is Leader of the Molecular Biomarkers Group and a Member of the Cancer Epidemiology, Head and Neck Cancer, and Lung ...
Genmab's HuMax-EGFr Awarded Fast Track Status From FDA Jan 3, 2006
PR Newswire (press release), Administration (FDA). This designation covers patients with head and neck cancer who have previously failed standard therapies. Genmab ...
Lecture series will complement exhibition, 'Saving Faces: Art and ... Dec 26, 2005
Lincoln Journal Star, Art and Science of Head and Neck Surgical and Related Interventions,� panel discussion headed by William Lydiatt, a UNMC head and neck cancer surgeon with ...
Merck KGaA Wins First Erbitux Approval for Head Cancer Dec 23, 2005
Cancerpage.com, FRANKFURT DEC 22, 2005 (Reuters) - Germany's Merck KGaA has won Swiss approval to market Erbitux (cetuximab) for treating head and neck cancer in combination ...
AVEO Pharmaceuticals Acquires Rights to Novel Anti-Cancer Compound ... Jan 5, 2006
PR Newswire (press release),
| |
